Author
Listed:
- Zhen Ning Wee
(Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research))
- Siti Maryam J. M. Yatim
(Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research))
- Vera K Kohlbauer
(Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research))
- Min Feng
(Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research))
- Jian Yuan Goh
(Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research))
- Yi Bao
(Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research))
- Puay Leng Lee
(Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research))
- Songjing Zhang
(Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research))
- Pan Pan Wang
(First Affiliated Hospital, Jinan University
Cancer Research Institute, Jinan University)
- Elgene Lim
(The Kinghorn Cancer Center, Garvan Institute of Medical Research)
- Wai Leong Tam
(Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research)
Cancer Science Institute, National University of Singapore)
- Yu Cai
(Cancer Research Institute, Jinan University
School of Pharmacy, Jinan University)
- Henrik J Ditzel
(Institute of Molecular Medicine, University of Southern Denmark
Odense University Hospital)
- Dave S. B. Hoon
(John Wayne Cancer Institute, Santa Monica, California 90404, USA)
- Ern Yu Tan
(Tan Tock Seng Hospital)
- Qiang Yu
(Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research)
Cancer Research Institute, Jinan University
Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
Cancer and Stem Cell Biology, DUKE-NUS Graduate Medical School of Singapore, Singapore 169857, Singapore)
Abstract
Metastatic tumour recurrence due to failed treatments remains a major challenge of breast cancer clinical management. Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer (TNBC), where it acts to drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment. We show that IRAK1 overexpression confers TNBC growth advantage through NF-κB-related cytokine secretion and metastatic TNBC cells exhibit gain of IRAK1 dependency, resulting in high susceptibility to genetic and pharmacologic inhibition of IRAK1. Importantly, paclitaxel treatment induces strong IRAK1 phosphorylation, an increase in inflammatory cytokine expression, enrichment of cancer stem cells and acquired resistance to paclitaxel treatment. Pharmacologic inhibition of IRAK1 is able to reverse paclitaxel resistance by triggering massive apoptosis at least in part through inhibiting p38-MCL1 pro-survival pathway. Our study thus demonstrates IRAK1 as a promising therapeutic target for TNBC metastasis and paclitaxel resistance.
Suggested Citation
Zhen Ning Wee & Siti Maryam J. M. Yatim & Vera K Kohlbauer & Min Feng & Jian Yuan Goh & Yi Bao & Puay Leng Lee & Songjing Zhang & Pan Pan Wang & Elgene Lim & Wai Leong Tam & Yu Cai & Henrik J Ditzel &, 2015.
"IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel,"
Nature Communications, Nature, vol. 6(1), pages 1-16, December.
Handle:
RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms9746
DOI: 10.1038/ncomms9746
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms9746. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.